Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8683 Bronchodilatory Effects in COPD
NCT01708057Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of AZD8683 in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Oct 2012; status: terminated.
02
Drugs
AZD8683
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01708057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01708057.